I-BET151 (GSK1210151A)

Catalog #
27629-1
$190 *
Size: 5 mg
Qty
*US Pricing only. For international pricing, please contact your local distributor.
Purchase
Description

I-BET151(GSK1210151A) is a BET bromodomain inhibitor. I-BET151 displays potent binding affinity to BRD2, BRD3 and BRD4 with Kd of 0.02-0.1 µM. I-BET151 (0.5 or 5 µM) inhibits the binding of BETs (BRD2, BRD3, BRD4, and BRD9) but not the binding of 23 other bromodomain proteins. I-BET151 also blocks recruitment of BET to chromatin.

This product has been cited 2 times.

Synonyms
I-BET151; GSK1210151A; 7-(3,5-dimethyl-1,2-oxazol-4-yl)-8-methoxy-1-[(1R)-1-pyridin-2-ylethyl]-3H-imidazo[4,5-c]quinolin-2-one
Product Info
Storage and Usage
Citations2
Target(s)
BET
Formula
C23H21N5O3
MW
415.4 Da
Solubility
Soluble in DMSO 83 mg/ml (199 mM), water < 1 mg/ml (<1 mM), ethanol 27 mg/ml (64 mM)
Biological Activity
I-BET151 (GSK1210151A) is a novel selective BET inhibitor for BRD2, BRD3 and BRD4 with IC50 of 0.5 µM, 0.25 µM, and 0.79 µM, respectively.
CAS Registry #
1300031-49-5
Background
Bromodomains have an important role in the targeting of chromatin-modifying enzymes to specific sites, including methyltransferases, HATs and transcription factors and regulate diverse biological processes from cell proliferation and differentiation to energy homeostasis and neurological processes. Optimized to retain excellent BET target potency and selectivity while enhancing the in vivo pharmacokinetics and terminal half-life to enable prolonged in vivo studies.
References
Dawson et al. (2011). Nature 478: 529.